On January 27, 2023 Bonnie J Addario Lung Cancer Foundation, reported that the U.S. Food and Drug Administration (FDA) approved Keytruda (pembrolizumab) for adjuvant (additional) treatment following surgery and chemotherapy for stage IB, II, or IIIA non-small cell lung cancer (NSCLC) (Press release, Bonnie J Addario Lung Cancer Foundation, JAN 27, 2023, View Source [SID1234626612]). This approval was based on the KEYNOTE-091 clinical trial where people who took Keytruda after surgery and chemotherapy lived significantly longer without a recurrence of the cancer than those who did not. This new approval provides another treatment option after surgery for people with early stage NSCLC

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!